(MENAFN- ProactiveInvestors - Australia) Invion (ASX: IVX) has initiated the phase II "NIMA" clinical trial to investigate the use of INV102 in patients with mild asthma.
The trail, which is funded by the U.S. National Institute of Allergy and Infectious Diseases through a cooperative agreement grant to Baylor University College of Medicine of about US$4.4 million will provide valuable data on INV102's effect on airway responsiveness.
This is a crucial part of assessing its potential as a treatment for lung diseases such as asthma and chronic bronchitis.
INV102, also known as nadolol, has been used in more than eight million people for the treatment of high blood pressure, migraine and chest pain.
The global market for asthma and chronic obstructive pulmonary disease prescription drugs was valued at $34 billion in 2011. This figure is increasing at a five year compound annual growth rate of 4.4%.
To date, two phase II clinical trials of INV102 have been completed which have demonstrated acceptable safety as well as dose-related reduction of airway hyper-responsiveness.
Chronic INV102 dosing resulted in a reduction in airway hyper-responsiveness comparable to results achieved with inhaled corticosteroids for several weeks.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.